Tag results:
SARS-CoV-2
Immunology of Infectious Disease News
Intranasal Administration of BReC-CoV-2 COVID-19 Vaccine Protects K18-hACE2 Mice against Lethal SARS-CoV-2 Challenge
[NPJ Vaccines] Scientists developed a prototype two-dose vaccine by combining the Receptor Binding Domain antigen, via conjugation to Diphtheria toxoid.
Immunology of Infectious Disease News
The RNA Helicase DHX16 Recognizes Specific Viral RNA to Trigger RIG-I-Dependent Innate Antiviral Immunity
[Cell Reports] Scientists identified the RNA helicase DHX16 as a potential pattern recognition receptor. Silencing of DHX16 in cells and in vivo diminished IFN-I responses against influenza virus.
Immunology of Infectious Disease News
RBD Trimer mRNA Vaccine Elicits Broad and Protective Immune Responses against SARS-CoV-2 Variants
[iScience] Researchers designed a lipid nanoparticle-encapsulated, nucleoside-unmodified mRNA vaccine encoding the trimerized receptor binding domain and showed its robust capability in inducing broad and protective immune responses against wildtype and major variants of concern in the mouse model of SARS-CoV-2 infection.
Immunology of Infectious Disease News
Mild SARS-CoV-2 Infection in Rhesus Macaques Is Associated with Viral Control Prior to Antigen-Specific T Cell Responses in Tissues
[Science Immunology] The authors used rhesus macaques to model protective primary immune responses in tissues during mild COVID-19.
Immunology of Infectious Disease News
Infection with the SARS-CoV-2 B.1.351 Variant Is Lethal in Aged BALB/C Mice
[Scientific Reports] Researchers demonstrated that infection with the SARS-CoV-2 B.1.351 variant induced bodyweight loss and inflammatory cytokine/chemokine production in wild-type laboratory mice.
Mesenchymal Cell News
Safety and Efficacy Study of Allogeneic Human Menstrual Blood Stromal Cells Secretome to Treat Severe COVID-19 Patients: Clinical Trial Phase I & II
[Stem Cell Research & Therapy] A prospective randomized double-blind placebo-controlled clinical trial assessed the safety and efficacy of secretome derived from allogeneic menstrual blood stromal cells as a treatment in patients with severe COVID-19.